Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2015 /
Pembrolizumab showed clinical benefit in malignant pleural mesothelioma

18th - 22nd Apr 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.04.15
Views: 2799

Dr Evan Alley - University of Pennsylvania, Philadelphia, USA

Dr Alley talks to ecancertv at AACR 2015 about the results of a phase I multi-centre trial looking at the use of pembrolizumab in the treatment of a variety of cancers. The drug showed signs of clinical benefit in patients with malignant pleural mesothelioma.

Read the news story for more.






Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation